Table 2.

Summary of short-term (≤6 weeks exposure) prospective studies examining the association of leptin polymorphisms and metabolic disturbances in antipsychotic use.

Author (year)	n (% male)	Population/ diagnosis	Medication	Dose	Treatment duration	SNPs studied	Summary of results	Ref.
Ellingrod et al (2007)	37(81)	Caucasian, schizophrenia	Olanzapine	12.43 ± 3.04 mg/day	6 weeks (min. 4 weeks)	LEP −2548G/A (rs7799039) LEPR Q223R† (rs1137101)	Significant interaction between the G allele of both LEPR and LEP variants and greater weight gain at higher serum concentrations (3.82 ± 3.31 kg/m2 vs 1.27 ± 1.74 kg/m2; p = 0.049)	[98]
Srivastava et al (2008)	130(41)	North Indian, schizophrenia and schizoaffective disorder	Olanzapine	16.5 ± 3.0 mg/day	6 weeks (3-day washout if prior AP exposure)	LEP (rs4731426) C/G	G allele was associated with above average (>2.17 kg) weight gain from baseline after 6 weeks (OR: 11.43; 95% CI: 1.49–87.55; p = 0.019)	[99]
						Leptin haplotype A-C-A-A-G‡	This haplotype associated with above average weight gain (>2.17 kg)

^†For LEPR Q223R polymorphism, G allele codes for R (arginine), A allele codes for Q (glutamine).

^‡Haplotype A-C-A-A-G: rs10487506 A/G–rs4731426 C/G–rs2278815 A/G–rs3828942 A/G–rs17151922 GIT.

AP: Antipsychotic; min.: Minimum; OR: Odds ratio.